Robert Andrade - 27 Aug 2026 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: FENC
Reported as of: 27 Aug 2026
Net transaction value: -$883,500
SEC form: 4
Accepted by SEC: 28 Aug 2026, 17:42:18 UTC
Prior SEC filing: 03 Aug 2026
Next SEC filing: 31 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Andrade

Key filing fact

Robert Andrade filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 28 Aug 2026.

Key facts

This page summarizes Robert Andrade's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Aug 2026, 17:42.

Change

Previous filing in this sequence was filed on 03 Aug 2026.
Current net transaction value: -$883,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001468308 Primary reporting owner

Andrade Robert

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O FENNEC PHARMACEUTICALS, INC., PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK
Signature: /s/ Robert Andrade
Signature date: 28 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FENC transaction

Common shares

Sale

Transaction value: $883,500
Shares: -75,000
Change %: -26%
Price: $11.78
Shares after: 217,675
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F1

FENC transaction

Common shares

Options Exercise

Transaction value
Shares: +21,928
Change %: +10%
Price: $5.10^*
Shares after: 239,603
Date: 28 Aug 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FENC transaction Derivative

Stock Options

Options Exercise

Transaction value
Shares: -21,928
Change %: -2.7%
Price: $0.000000^*
Shares after: 779,330
Date: 28 Aug 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 21,928
Exercise price: $5.10
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). A portion of the sales proceeds from this transaction will be used by the reporting person to pay tax obligations of the reporting person.

Footnote F2

Shares acquired through the exercise of an option contract with exercise price of $5.10 and an expiration date of June 27, 2027.